Aix-Marseille Université, IRD, APHM, MEPHI, Marseille, France.
IHU-Méditerranée Infection, Marseille, France.
Mycoses. 2022 Jul;65(7):753-759. doi: 10.1111/myc.13470. Epub 2022 May 31.
Currently, Candida auris is among the most serious emerging pathogens that can be associated with nosocomial infections and outbreaks in intensive care units. Clinicians must be able to identify and manage it quickly.
Here, we report for the first time in Algeria seven cases of C. auris infection or colonisation.
The strains were isolated from clinical sites including bronchial aspirates (n = 4), wound swabs (n = 1), urine sample (n = 1) and peritoneal fluid (n = 1), in patients admitted to the intensive care unit. Candida auris was identified both by MALDI-TOF and by sequencing the ITS region and the D1/D2 domain. Antifungal susceptibility testing was performed using the E-test method. Non-wildtype susceptibility was observed for five strains against fluconazole, itraconazole, voriconazole and caspofungin. Genotyping showed the presence of four clades (I-IV) in one hospital.
Appropriate antifungal treatments with rapid and accurate microbial identification are the cornerstone for the management and control of C. auris infections.
目前，耳念珠菌是最严重的新兴病原体之一，可引起医院感染和重症监护病房的暴发。临床医生必须能够快速识别和管理它。
我们首次在阿尔及利亚报告了 7 例耳念珠菌感染或定植病例。
这些菌株从包括支气管吸出物（n=4）、伤口拭子（n=1）、尿液样本（n=1）和腹腔液（n=1）在内的临床部位分离出来，患者均入住重症监护病房。通过 MALDI-TOF 和 ITS 区和 D1/D2 结构域测序鉴定出耳念珠菌。使用 E 试验法进行抗真菌药敏试验。5 株对氟康唑、伊曲康唑、伏立康唑和卡泊芬净的非野生型药敏性进行了检测。基因分型显示在一家医院存在 4 个分支（I-IV）。
快速准确的微生物鉴定和适当的抗真菌治疗是管理和控制耳念珠菌感染的基础。
